nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—HTR1D—meninx—brain cancer	0.0228	0.0464	CbGeAlD
Loxapine—HTR3A—fourth ventricle—brain cancer	0.0222	0.0452	CbGeAlD
Loxapine—HTR1B—dura mater—brain cancer	0.0217	0.0441	CbGeAlD
Loxapine—HTR1D—dura mater—brain cancer	0.021	0.0427	CbGeAlD
Loxapine—HTR2C—choroid plexus—brain cancer	0.0177	0.0359	CbGeAlD
Loxapine—Slurred speech—Procarbazine—brain cancer	0.01	0.0373	CcSEcCtD
Loxapine—HTR1B—trigeminal nerve—brain cancer	0.00932	0.019	CbGeAlD
Loxapine—DRD3—telencephalic ventricle—brain cancer	0.0093	0.0189	CbGeAlD
Loxapine—HTR1D—trigeminal nerve—brain cancer	0.00902	0.0183	CbGeAlD
Loxapine—HTR2A—choroid plexus—brain cancer	0.00886	0.018	CbGeAlD
Loxapine—HTR3A—cranial nerve—brain cancer	0.00791	0.0161	CbGeAlD
Loxapine—Dysarthria—Lomustine—brain cancer	0.00746	0.0278	CcSEcCtD
Loxapine—HRH1—nose—brain cancer	0.00684	0.0139	CbGeAlD
Loxapine—DRD1—telencephalic ventricle—brain cancer	0.00666	0.0136	CbGeAlD
Loxapine—HTR1B—cranial nerve—brain cancer	0.00664	0.0135	CbGeAlD
Loxapine—HTR7—vein—brain cancer	0.00649	0.0132	CbGeAlD
Loxapine—HTR1D—cranial nerve—brain cancer	0.00643	0.0131	CbGeAlD
Loxapine—Trifluoperazine—S100A4—brain cancer	0.00629	0.42	CrCbGaD
Loxapine—HTR6—ganglion—brain cancer	0.00557	0.0113	CbGeAlD
Loxapine—DRD5—ganglion—brain cancer	0.00543	0.011	CbGeAlD
Loxapine—HTR1B—telencephalic ventricle—brain cancer	0.0054	0.011	CbGeAlD
Loxapine—SLC6A3—telencephalic ventricle—brain cancer	0.00535	0.0109	CbGeAlD
Loxapine—HTR1D—telencephalic ventricle—brain cancer	0.00523	0.0106	CbGeAlD
Loxapine—HTR2C—telencephalic ventricle—brain cancer	0.00517	0.0105	CbGeAlD
Loxapine—HTR7—cranial nerve—brain cancer	0.00512	0.0104	CbGeAlD
Loxapine—Amenorrhoea—Procarbazine—brain cancer	0.0051	0.019	CcSEcCtD
Loxapine—HTR7—pons—brain cancer	0.00506	0.0103	CbGeAlD
Loxapine—Dysarthria—Procarbazine—brain cancer	0.00474	0.0176	CcSEcCtD
Loxapine—HTR2A—trigeminal nerve—brain cancer	0.00448	0.00911	CbGeAlD
Loxapine—HTR2A—cerebellar cortex—brain cancer	0.00446	0.00908	CbGeAlD
Loxapine—Throat tightness—Etoposide—brain cancer	0.00442	0.0165	CcSEcCtD
Loxapine—HTR1A—telencephalic ventricle—brain cancer	0.00436	0.00886	CbGeAlD
Loxapine—HTR7—telencephalic ventricle—brain cancer	0.00416	0.00847	CbGeAlD
Loxapine—DRD1—ganglion—brain cancer	0.00415	0.00844	CbGeAlD
Loxapine—HTR2A—vein—brain cancer	0.00405	0.00824	CbGeAlD
Loxapine—Gynaecomastia—Procarbazine—brain cancer	0.00401	0.0149	CcSEcCtD
Loxapine—HTR3A—ganglion—brain cancer	0.004	0.00815	CbGeAlD
Loxapine—HTR5A—head—brain cancer	0.004	0.00813	CbGeAlD
Loxapine—Amenorrhoea—Hydroxyurea—brain cancer	0.00395	0.0147	CcSEcCtD
Loxapine—DRD2—telencephalic ventricle—brain cancer	0.00394	0.00801	CbGeAlD
Loxapine—Renal failure—Lomustine—brain cancer	0.00388	0.0145	CcSEcCtD
Loxapine—Photosensitivity—Procarbazine—brain cancer	0.0037	0.0138	CcSEcCtD
Loxapine—HTR5A—central nervous system—brain cancer	0.00365	0.00742	CbGeAlD
Loxapine—Extrapyramidal disorder—Temozolomide—brain cancer	0.0036	0.0134	CcSEcCtD
Loxapine—HTR1B—ganglion—brain cancer	0.00336	0.00683	CbGeAlD
Loxapine—SLC6A3—ganglion—brain cancer	0.00333	0.00678	CbGeAlD
Loxapine—HTR1D—ganglion—brain cancer	0.00325	0.00662	CbGeAlD
Loxapine—HTR2C—ganglion—brain cancer	0.00322	0.00655	CbGeAlD
Loxapine—Liver injury—Temozolomide—brain cancer	0.00322	0.012	CcSEcCtD
Loxapine—HTR2A—cranial nerve—brain cancer	0.00319	0.00649	CbGeAlD
Loxapine—HTR2A—pons—brain cancer	0.00315	0.00642	CbGeAlD
Loxapine—Alopecia—Lomustine—brain cancer	0.00313	0.0117	CcSEcCtD
Loxapine—HTR1E—brainstem—brain cancer	0.00309	0.00628	CbGeAlD
Loxapine—Amenorrhoea—Temozolomide—brain cancer	0.00308	0.0115	CcSEcCtD
Loxapine—SLC6A4—ganglion—brain cancer	0.00305	0.00621	CbGeAlD
Loxapine—HTR5A—brain—brain cancer	0.0029	0.00589	CbGeAlD
Loxapine—Gait disturbance—Carmustine—brain cancer	0.00287	0.0107	CcSEcCtD
Loxapine—Dysphagia—Procarbazine—brain cancer	0.00281	0.0105	CcSEcCtD
Loxapine—Gait disturbance—Temozolomide—brain cancer	0.00277	0.0103	CcSEcCtD
Loxapine—Leukopenia—Lomustine—brain cancer	0.00276	0.0103	CcSEcCtD
Loxapine—HTR1E—telencephalon—brain cancer	0.00274	0.00557	CbGeAlD
Loxapine—HTR1A—ganglion—brain cancer	0.00271	0.00552	CbGeAlD
Loxapine—SLC6A2—ganglion—brain cancer	0.00269	0.00547	CbGeAlD
Loxapine—HTR1B—blood vessel—brain cancer	0.00267	0.00543	CbGeAlD
Loxapine—Numbness—Etoposide—brain cancer	0.00261	0.00974	CcSEcCtD
Loxapine—HTR2A—telencephalic ventricle—brain cancer	0.0026	0.00528	CbGeAlD
Loxapine—HTR7—ganglion—brain cancer	0.00259	0.00527	CbGeAlD
Loxapine—HTR1D—blood vessel—brain cancer	0.00259	0.00526	CbGeAlD
Loxapine—Photosensitivity reaction—Procarbazine—brain cancer	0.00256	0.00956	CcSEcCtD
Loxapine—SLC6A3—hindbrain—brain cancer	0.00253	0.00514	CbGeAlD
Loxapine—Gynaecomastia—Carmustine—brain cancer	0.00251	0.00934	CcSEcCtD
Loxapine—Drowsiness—Procarbazine—brain cancer	0.00251	0.00934	CcSEcCtD
Loxapine—Sensory loss—Etoposide—brain cancer	0.0025	0.00932	CcSEcCtD
Loxapine—Dry eye—Temozolomide—brain cancer	0.0025	0.00932	CcSEcCtD
Loxapine—Thrombocytopenia—Lomustine—brain cancer	0.00246	0.00918	CcSEcCtD
Loxapine—DRD2—ganglion—brain cancer	0.00245	0.00498	CbGeAlD
Loxapine—Chest discomfort—Etoposide—brain cancer	0.00245	0.00913	CcSEcCtD
Loxapine—Jaundice—Procarbazine—brain cancer	0.00244	0.0091	CcSEcCtD
Loxapine—SLC6A4—hindbrain—brain cancer	0.00232	0.00471	CbGeAlD
Loxapine—HTR2A—pineal body—brain cancer	0.00225	0.00458	CbGeAlD
Loxapine—HTR7—endothelium—brain cancer	0.00223	0.00454	CbGeAlD
Loxapine—Nasal congestion—Temozolomide—brain cancer	0.00216	0.00804	CcSEcCtD
Loxapine—HTR6—telencephalon—brain cancer	0.00215	0.00437	CbGeAlD
Loxapine—DRD5—telencephalon—brain cancer	0.00209	0.00426	CbGeAlD
Loxapine—HTR7—blood vessel—brain cancer	0.00206	0.00419	CbGeAlD
Loxapine—HTR1A—hindbrain—brain cancer	0.00206	0.00418	CbGeAlD
Loxapine—Alopecia—Procarbazine—brain cancer	0.00199	0.00741	CcSEcCtD
Loxapine—Weight increased—Hydroxyurea—brain cancer	0.00198	0.00738	CcSEcCtD
Loxapine—HTR7—hindbrain—brain cancer	0.00196	0.004	CbGeAlD
Loxapine—Drowsiness—Hydroxyurea—brain cancer	0.00194	0.00723	CcSEcCtD
Loxapine—Tension—Procarbazine—brain cancer	0.00192	0.00716	CcSEcCtD
Loxapine—ADRA1A—hindbrain—brain cancer	0.0019	0.00386	CbGeAlD
Loxapine—Cyclizine—CYP2C9—brain cancer	0.00189	0.126	CrCbGaD
Loxapine—DRD2—hindbrain—brain cancer	0.00186	0.00378	CbGeAlD
Loxapine—Tremor—Procarbazine—brain cancer	0.00183	0.00684	CcSEcCtD
Loxapine—DRD1—brainstem—brain cancer	0.0018	0.00367	CbGeAlD
Loxapine—Dysphagia—Carmustine—brain cancer	0.00176	0.00655	CcSEcCtD
Loxapine—Syncope—Procarbazine—brain cancer	0.00176	0.00654	CcSEcCtD
Loxapine—Leukopenia—Procarbazine—brain cancer	0.00175	0.00653	CcSEcCtD
Loxapine—HTR3A—brainstem—brain cancer	0.00174	0.00354	CbGeAlD
Loxapine—Loss of consciousness—Procarbazine—brain cancer	0.00172	0.00641	CcSEcCtD
Loxapine—Cough—Procarbazine—brain cancer	0.00171	0.00637	CcSEcCtD
Loxapine—HTR1E—head—brain cancer	0.00171	0.00347	CbGeAlD
Loxapine—Dysphagia—Temozolomide—brain cancer	0.0017	0.00633	CcSEcCtD
Loxapine—Convulsion—Procarbazine—brain cancer	0.0017	0.00632	CcSEcCtD
Loxapine—Hypertension—Procarbazine—brain cancer	0.00169	0.0063	CcSEcCtD
Loxapine—Azelastine—CYP2C9—brain cancer	0.00167	0.111	CrCbGaD
Loxapine—Dry mouth—Procarbazine—brain cancer	0.00163	0.00608	CcSEcCtD
Loxapine—HTR2A—ganglion—brain cancer	0.00162	0.00329	CbGeAlD
Loxapine—Confusional state—Procarbazine—brain cancer	0.00161	0.006	CcSEcCtD
Loxapine—Vomiting—Lomustine—brain cancer	0.0016	0.00596	CcSEcCtD
Loxapine—DRD1—telencephalon—brain cancer	0.0016	0.00325	CbGeAlD
Loxapine—Oedema—Procarbazine—brain cancer	0.0016	0.00596	CcSEcCtD
Loxapine—Angiopathy—Hydroxyurea—brain cancer	0.00158	0.00589	CcSEcCtD
Loxapine—Shock—Procarbazine—brain cancer	0.00157	0.00586	CcSEcCtD
Loxapine—Thrombocytopenia—Procarbazine—brain cancer	0.00156	0.00583	CcSEcCtD
Loxapine—Tachycardia—Procarbazine—brain cancer	0.00156	0.00581	CcSEcCtD
Loxapine—HTR1E—central nervous system—brain cancer	0.00156	0.00317	CbGeAlD
Loxapine—Photosensitivity reaction—Temozolomide—brain cancer	0.00155	0.00578	CcSEcCtD
Loxapine—Weight increased—Temozolomide—brain cancer	0.00155	0.00576	CcSEcCtD
Loxapine—HTR3A—telencephalon—brain cancer	0.00154	0.00314	CbGeAlD
Loxapine—Renal failure—Carmustine—brain cancer	0.00154	0.00574	CcSEcCtD
Loxapine—Alopecia—Hydroxyurea—brain cancer	0.00154	0.00573	CcSEcCtD
Loxapine—Weight decreased—Temozolomide—brain cancer	0.00154	0.00573	CcSEcCtD
Loxapine—CHRM4—head—brain cancer	0.0015	0.00304	CbGeAlD
Loxapine—Nausea—Lomustine—brain cancer	0.0015	0.00557	CcSEcCtD
Loxapine—Hypotension—Procarbazine—brain cancer	0.00149	0.00556	CcSEcCtD
Loxapine—HTR1B—brainstem—brain cancer	0.00146	0.00297	CbGeAlD
Loxapine—SLC6A3—brainstem—brain cancer	0.00145	0.00295	CbGeAlD
Loxapine—Insomnia—Procarbazine—brain cancer	0.00145	0.00539	CcSEcCtD
Loxapine—Paraesthesia—Procarbazine—brain cancer	0.00143	0.00535	CcSEcCtD
Loxapine—DRD4—brain—brain cancer	0.00143	0.00292	CbGeAlD
Loxapine—Olanzapine—CYP2C9—brain cancer	0.00143	0.0955	CrCbGaD
Loxapine—Somnolence—Procarbazine—brain cancer	0.00142	0.00529	CcSEcCtD
Loxapine—HTR1D—brainstem—brain cancer	0.00141	0.00288	CbGeAlD
Loxapine—Hypoaesthesia—Carmustine—brain cancer	0.0014	0.00522	CcSEcCtD
Loxapine—HTR2C—brainstem—brain cancer	0.0014	0.00285	CbGeAlD
Loxapine—HTR2A—endothelium—brain cancer	0.00139	0.00283	CbGeAlD
Loxapine—DRD3—head—brain cancer	0.00139	0.00283	CbGeAlD
Loxapine—Fatigue—Procarbazine—brain cancer	0.00138	0.00513	CcSEcCtD
Loxapine—Constipation—Procarbazine—brain cancer	0.00137	0.00509	CcSEcCtD
Loxapine—CHRM4—central nervous system—brain cancer	0.00137	0.00278	CbGeAlD
Loxapine—Hepatitis—Temozolomide—brain cancer	0.00136	0.00507	CcSEcCtD
Loxapine—Dysphagia—Etoposide—brain cancer	0.00136	0.00507	CcSEcCtD
Loxapine—Leukopenia—Hydroxyurea—brain cancer	0.00136	0.00505	CcSEcCtD
Loxapine—Hypoaesthesia—Temozolomide—brain cancer	0.00135	0.00504	CcSEcCtD
Loxapine—HTR6—head—brain cancer	0.00134	0.00272	CbGeAlD
Loxapine—Bronchospasm—Etoposide—brain cancer	0.00134	0.00498	CcSEcCtD
Loxapine—SLC6A4—brainstem—brain cancer	0.00133	0.0027	CbGeAlD
Loxapine—DRD5—endocrine gland—brain cancer	0.00132	0.00269	CbGeAlD
Loxapine—Feeling abnormal—Procarbazine—brain cancer	0.00132	0.00491	CcSEcCtD
Loxapine—Convulsion—Hydroxyurea—brain cancer	0.00131	0.00489	CcSEcCtD
Loxapine—DRD5—head—brain cancer	0.0013	0.00265	CbGeAlD
Loxapine—HTR1B—telencephalon—brain cancer	0.0013	0.00264	CbGeAlD
Loxapine—Alprazolam—CYP2C9—brain cancer	0.0013	0.0864	CrCbGaD
Loxapine—CHRM2—telencephalon—brain cancer	0.00129	0.00262	CbGeAlD
Loxapine—SLC6A3—telencephalon—brain cancer	0.00129	0.00261	CbGeAlD
Loxapine—HTR2A—blood vessel—brain cancer	0.00128	0.00261	CbGeAlD
Loxapine—DRD3—central nervous system—brain cancer	0.00127	0.00258	CbGeAlD
Loxapine—HTR1D—telencephalon—brain cancer	0.00125	0.00255	CbGeAlD
Loxapine—Alopecia—Carmustine—brain cancer	0.00124	0.00463	CcSEcCtD
Loxapine—HTR2C—telencephalon—brain cancer	0.00124	0.00253	CbGeAlD
Loxapine—HRH2—endocrine gland—brain cancer	0.00124	0.00252	CbGeAlD
Loxapine—Oedema—Hydroxyurea—brain cancer	0.00124	0.00461	CcSEcCtD
Loxapine—HTR1E—brain—brain cancer	0.00124	0.00252	CbGeAlD
Loxapine—Angiopathy—Temozolomide—brain cancer	0.00123	0.0046	CcSEcCtD
Loxapine—Mediastinal disorder—Temozolomide—brain cancer	0.00123	0.00457	CcSEcCtD
Loxapine—HTR2A—hindbrain—brain cancer	0.00123	0.00249	CbGeAlD
Loxapine—HRH2—head—brain cancer	0.00122	0.00249	CbGeAlD
Loxapine—HTR6—central nervous system—brain cancer	0.00122	0.00249	CbGeAlD
Loxapine—ADRB1—telencephalon—brain cancer	0.00122	0.00248	CbGeAlD
Loxapine—Nervous system disorder—Hydroxyurea—brain cancer	0.00121	0.00452	CcSEcCtD
Loxapine—Thrombocytopenia—Hydroxyurea—brain cancer	0.00121	0.00451	CcSEcCtD
Loxapine—Alopecia—Temozolomide—brain cancer	0.0012	0.00448	CcSEcCtD
Loxapine—Renal failure—Etoposide—brain cancer	0.00119	0.00444	CcSEcCtD
Loxapine—DRD5—central nervous system—brain cancer	0.00119	0.00242	CbGeAlD
Loxapine—Jaundice—Etoposide—brain cancer	0.00118	0.0044	CcSEcCtD
Loxapine—HTR1A—brainstem—brain cancer	0.00118	0.0024	CbGeAlD
Loxapine—SLC6A4—telencephalon—brain cancer	0.00118	0.0024	CbGeAlD
Loxapine—Hypersensitivity—Procarbazine—brain cancer	0.00118	0.00439	CcSEcCtD
Loxapine—CHRM1—telencephalon—brain cancer	0.00117	0.00239	CbGeAlD
Loxapine—CHRM5—head—brain cancer	0.00117	0.00238	CbGeAlD
Loxapine—SLC6A2—brainstem—brain cancer	0.00117	0.00238	CbGeAlD
Loxapine—Dysgeusia—Temozolomide—brain cancer	0.00116	0.00432	CcSEcCtD
Loxapine—Vision blurred—Carmustine—brain cancer	0.00115	0.0043	CcSEcCtD
Loxapine—DRD1—midbrain—brain cancer	0.00115	0.00234	CbGeAlD
Loxapine—Tremor—Carmustine—brain cancer	0.00115	0.00428	CcSEcCtD
Loxapine—Asthenia—Procarbazine—brain cancer	0.00115	0.00427	CcSEcCtD
Loxapine—Agranulocytosis—Etoposide—brain cancer	0.00113	0.00422	CcSEcCtD
Loxapine—Pruritus—Procarbazine—brain cancer	0.00113	0.00421	CcSEcCtD
Loxapine—HTR7—brainstem—brain cancer	0.00113	0.00229	CbGeAlD
Loxapine—Agitation—Carmustine—brain cancer	0.00113	0.0042	CcSEcCtD
Loxapine—HRH2—central nervous system—brain cancer	0.00112	0.00227	CbGeAlD
Loxapine—Vision blurred—Temozolomide—brain cancer	0.00112	0.00416	CcSEcCtD
Loxapine—Tremor—Temozolomide—brain cancer	0.00111	0.00413	CcSEcCtD
Loxapine—Dyspnoea—Hydroxyurea—brain cancer	0.0011	0.00411	CcSEcCtD
Loxapine—Somnolence—Hydroxyurea—brain cancer	0.0011	0.0041	CcSEcCtD
Loxapine—Leukopenia—Carmustine—brain cancer	0.0011	0.00409	CcSEcCtD
Loxapine—Agitation—Temozolomide—brain cancer	0.00109	0.00405	CcSEcCtD
Loxapine—ADRA1A—brainstem—brain cancer	0.00109	0.00221	CbGeAlD
Loxapine—CHRM4—brain—brain cancer	0.00108	0.00221	CbGeAlD
Loxapine—Hypoaesthesia—Etoposide—brain cancer	0.00108	0.00403	CcSEcCtD
Loxapine—ADRA1B—head—brain cancer	0.00107	0.00217	CbGeAlD
Loxapine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00107	0.00398	CcSEcCtD
Loxapine—CHRM5—central nervous system—brain cancer	0.00107	0.00217	CbGeAlD
Loxapine—Fatigue—Hydroxyurea—brain cancer	0.00107	0.00397	CcSEcCtD
Loxapine—DRD2—brainstem—brain cancer	0.00106	0.00217	CbGeAlD
Loxapine—Convulsion—Carmustine—brain cancer	0.00106	0.00396	CcSEcCtD
Loxapine—Leukopenia—Temozolomide—brain cancer	0.00106	0.00395	CcSEcCtD
Loxapine—Hypertension—Carmustine—brain cancer	0.00106	0.00394	CcSEcCtD
Loxapine—Constipation—Hydroxyurea—brain cancer	0.00106	0.00394	CcSEcCtD
Loxapine—Dizziness—Procarbazine—brain cancer	0.00106	0.00394	CcSEcCtD
Loxapine—CHRM3—telencephalon—brain cancer	0.00105	0.00214	CbGeAlD
Loxapine—HTR1A—telencephalon—brain cancer	0.00105	0.00213	CbGeAlD
Loxapine—Chest pain—Carmustine—brain cancer	0.00104	0.00389	CcSEcCtD
Loxapine—SLC6A2—telencephalon—brain cancer	0.00104	0.00211	CbGeAlD
Loxapine—Cough—Temozolomide—brain cancer	0.00103	0.00385	CcSEcCtD
Loxapine—Convulsion—Temozolomide—brain cancer	0.00103	0.00382	CcSEcCtD
Loxapine—Hypertension—Temozolomide—brain cancer	0.00102	0.00381	CcSEcCtD
Loxapine—Feeling abnormal—Hydroxyurea—brain cancer	0.00102	0.0038	CcSEcCtD
Loxapine—Vomiting—Procarbazine—brain cancer	0.00102	0.00379	CcSEcCtD
Loxapine—Confusional state—Carmustine—brain cancer	0.00101	0.00376	CcSEcCtD
Loxapine—DRD3—brain—brain cancer	0.00101	0.00205	CbGeAlD
Loxapine—Rash—Procarbazine—brain cancer	0.00101	0.00375	CcSEcCtD
Loxapine—Dermatitis—Procarbazine—brain cancer	0.00101	0.00375	CcSEcCtD
Loxapine—Headache—Procarbazine—brain cancer	0.001	0.00373	CcSEcCtD
Loxapine—Oedema—Carmustine—brain cancer	0.001	0.00373	CcSEcCtD
Loxapine—HTR7—telencephalon—brain cancer	0.000999	0.00203	CbGeAlD
Loxapine—DRD1—head—brain cancer	0.000996	0.00203	CbGeAlD
Loxapine—Angiopathy—Etoposide—brain cancer	0.000987	0.00368	CcSEcCtD
Loxapine—Dry mouth—Temozolomide—brain cancer	0.000986	0.00367	CcSEcCtD
Loxapine—Mediastinal disorder—Etoposide—brain cancer	0.000981	0.00365	CcSEcCtD
Loxapine—Thrombocytopenia—Carmustine—brain cancer	0.000979	0.00365	CcSEcCtD
Loxapine—HTR2C—medulla oblongata—brain cancer	0.000976	0.00199	CbGeAlD
Loxapine—Tachycardia—Carmustine—brain cancer	0.000976	0.00364	CcSEcCtD
Loxapine—ADRA1B—central nervous system—brain cancer	0.000975	0.00198	CbGeAlD
Loxapine—Confusional state—Temozolomide—brain cancer	0.000974	0.00363	CcSEcCtD
Loxapine—HTR6—brain—brain cancer	0.00097	0.00197	CbGeAlD
Loxapine—Oedema—Temozolomide—brain cancer	0.000966	0.0036	CcSEcCtD
Loxapine—ADRA1A—telencephalon—brain cancer	0.000964	0.00196	CbGeAlD
Loxapine—HTR3A—head—brain cancer	0.000962	0.00196	CbGeAlD
Loxapine—Alopecia—Etoposide—brain cancer	0.000962	0.00358	CcSEcCtD
Loxapine—Nausea—Procarbazine—brain cancer	0.000949	0.00354	CcSEcCtD
Loxapine—Nervous system disorder—Temozolomide—brain cancer	0.000947	0.00353	CcSEcCtD
Loxapine—Thrombocytopenia—Temozolomide—brain cancer	0.000946	0.00353	CcSEcCtD
Loxapine—DRD2—telencephalon—brain cancer	0.000945	0.00192	CbGeAlD
Loxapine—DRD5—brain—brain cancer	0.000945	0.00192	CbGeAlD
Loxapine—Hypotension—Carmustine—brain cancer	0.000934	0.00348	CcSEcCtD
Loxapine—HTR1B—midbrain—brain cancer	0.000931	0.00189	CbGeAlD
Loxapine—Dysgeusia—Etoposide—brain cancer	0.000928	0.00346	CcSEcCtD
Loxapine—SLC6A3—midbrain—brain cancer	0.000923	0.00188	CbGeAlD
Loxapine—ADRA2C—telencephalon—brain cancer	0.000919	0.00187	CbGeAlD
Loxapine—Hypersensitivity—Hydroxyurea—brain cancer	0.000911	0.0034	CcSEcCtD
Loxapine—Muscle spasms—Etoposide—brain cancer	0.000911	0.00339	CcSEcCtD
Loxapine—Temazepam—CYP2C9—brain cancer	0.00091	0.0607	CrCbGaD
Loxapine—DRD1—central nervous system—brain cancer	0.000909	0.00185	CbGeAlD
Loxapine—HTR1B—spinal cord—brain cancer	0.000908	0.00185	CbGeAlD
Loxapine—Insomnia—Carmustine—brain cancer	0.000904	0.00337	CcSEcCtD
Loxapine—HTR1D—midbrain—brain cancer	0.000901	0.00183	CbGeAlD
Loxapine—SLC6A3—spinal cord—brain cancer	0.000901	0.00183	CbGeAlD
Loxapine—Paraesthesia—Carmustine—brain cancer	0.000898	0.00335	CcSEcCtD
Loxapine—HTR2C—midbrain—brain cancer	0.000892	0.00182	CbGeAlD
Loxapine—Dyspnoea—Carmustine—brain cancer	0.000891	0.00332	CcSEcCtD
Loxapine—Somnolence—Carmustine—brain cancer	0.000889	0.00331	CcSEcCtD
Loxapine—Asthenia—Hydroxyurea—brain cancer	0.000887	0.00331	CcSEcCtD
Loxapine—HRH2—brain—brain cancer	0.000887	0.0018	CbGeAlD
Loxapine—HTR3A—central nervous system—brain cancer	0.000878	0.00179	CbGeAlD
Loxapine—Insomnia—Temozolomide—brain cancer	0.000874	0.00326	CcSEcCtD
Loxapine—HTR2C—spinal cord—brain cancer	0.000871	0.00177	CbGeAlD
Loxapine—Paraesthesia—Temozolomide—brain cancer	0.000868	0.00323	CcSEcCtD
Loxapine—SLC6A2—gonad—brain cancer	0.000865	0.00176	CbGeAlD
Loxapine—Gastrointestinal disorder—Carmustine—brain cancer	0.000863	0.00322	CcSEcCtD
Loxapine—Dyspnoea—Temozolomide—brain cancer	0.000861	0.00321	CcSEcCtD
Loxapine—Somnolence—Temozolomide—brain cancer	0.000859	0.0032	CcSEcCtD
Loxapine—Constipation—Carmustine—brain cancer	0.000855	0.00319	CcSEcCtD
Loxapine—Leukopenia—Etoposide—brain cancer	0.000848	0.00316	CcSEcCtD
Loxapine—CHRM5—brain—brain cancer	0.000847	0.00172	CbGeAlD
Loxapine—SLC6A4—midbrain—brain cancer	0.000846	0.00172	CbGeAlD
Loxapine—HTR7—gonad—brain cancer	0.000834	0.0017	CbGeAlD
Loxapine—Gastrointestinal disorder—Temozolomide—brain cancer	0.000834	0.00311	CcSEcCtD
Loxapine—Fatigue—Temozolomide—brain cancer	0.000833	0.0031	CcSEcCtD
Loxapine—Loss of consciousness—Etoposide—brain cancer	0.000833	0.0031	CcSEcCtD
Loxapine—Cough—Etoposide—brain cancer	0.000827	0.00308	CcSEcCtD
Loxapine—Constipation—Temozolomide—brain cancer	0.000826	0.00308	CcSEcCtD
Loxapine—SLC6A4—spinal cord—brain cancer	0.000825	0.00168	CbGeAlD
Loxapine—Feeling abnormal—Carmustine—brain cancer	0.000824	0.00307	CcSEcCtD
Loxapine—Convulsion—Etoposide—brain cancer	0.000821	0.00306	CcSEcCtD
Loxapine—Hypertension—Etoposide—brain cancer	0.000818	0.00305	CcSEcCtD
Loxapine—Dizziness—Hydroxyurea—brain cancer	0.000818	0.00305	CcSEcCtD
Loxapine—HTR1B—endocrine gland—brain cancer	0.000817	0.00166	CbGeAlD
Loxapine—SLC6A2—medulla oblongata—brain cancer	0.000815	0.00166	CbGeAlD
Loxapine—CHRM2—endocrine gland—brain cancer	0.000813	0.00165	CbGeAlD
Loxapine—HTR1B—head—brain cancer	0.000807	0.00164	CbGeAlD
Loxapine—Chest pain—Etoposide—brain cancer	0.000806	0.00301	CcSEcCtD
Loxapine—CHRM2—head—brain cancer	0.000803	0.00163	CbGeAlD
Loxapine—SLC6A3—head—brain cancer	0.0008	0.00163	CbGeAlD
Loxapine—Feeling abnormal—Temozolomide—brain cancer	0.000796	0.00297	CcSEcCtD
Loxapine—Vomiting—Hydroxyurea—brain cancer	0.000786	0.00293	CcSEcCtD
Loxapine—HTR7—medulla oblongata—brain cancer	0.000785	0.0016	CbGeAlD
Loxapine—HTR1D—head—brain cancer	0.000781	0.00159	CbGeAlD
Loxapine—Rash—Hydroxyurea—brain cancer	0.00078	0.00291	CcSEcCtD
Loxapine—Confusional state—Etoposide—brain cancer	0.00078	0.00291	CcSEcCtD
Loxapine—Dermatitis—Hydroxyurea—brain cancer	0.000779	0.0029	CcSEcCtD
Loxapine—Headache—Hydroxyurea—brain cancer	0.000775	0.00289	CcSEcCtD
Loxapine—ADRA1B—brain—brain cancer	0.000774	0.00158	CbGeAlD
Loxapine—HTR2C—head—brain cancer	0.000774	0.00157	CbGeAlD
Loxapine—DRD2—pituitary gland—brain cancer	0.000769	0.00157	CbGeAlD
Loxapine—ADRB1—endocrine gland—brain cancer	0.000769	0.00156	CbGeAlD
Loxapine—ADRB1—head—brain cancer	0.000759	0.00154	CbGeAlD
Loxapine—Thrombocytopenia—Etoposide—brain cancer	0.000757	0.00282	CcSEcCtD
Loxapine—Diazepam—CYP2C9—brain cancer	0.000756	0.0505	CrCbGaD
Loxapine—Tachycardia—Etoposide—brain cancer	0.000755	0.00281	CcSEcCtD
Loxapine—HTR1A—midbrain—brain cancer	0.000751	0.00153	CbGeAlD
Loxapine—ADRA2C—pituitary gland—brain cancer	0.000748	0.00152	CbGeAlD
Loxapine—Clozapine—CYP2C9—brain cancer	0.000747	0.0498	CrCbGaD
Loxapine—HRH1—telencephalon—brain cancer	0.000746	0.00152	CbGeAlD
Loxapine—SLC6A4—endocrine gland—brain cancer	0.000743	0.00151	CbGeAlD
Loxapine—CHRM1—endocrine gland—brain cancer	0.00074	0.00151	CbGeAlD
Loxapine—HTR1B—central nervous system—brain cancer	0.000737	0.0015	CbGeAlD
Loxapine—Hypersensitivity—Carmustine—brain cancer	0.000737	0.00275	CcSEcCtD
Loxapine—Nausea—Hydroxyurea—brain cancer	0.000735	0.00274	CcSEcCtD
Loxapine—SLC6A4—head—brain cancer	0.000733	0.00149	CbGeAlD
Loxapine—ADRA2A—telencephalon—brain cancer	0.000733	0.00149	CbGeAlD
Loxapine—HTR1A—spinal cord—brain cancer	0.000733	0.00149	CbGeAlD
Loxapine—CHRM2—central nervous system—brain cancer	0.000733	0.00149	CbGeAlD
Loxapine—CHRM1—head—brain cancer	0.000731	0.00149	CbGeAlD
Loxapine—SLC6A3—central nervous system—brain cancer	0.000731	0.00149	CbGeAlD
Loxapine—Hypotension—Etoposide—brain cancer	0.000722	0.00269	CcSEcCtD
Loxapine—ADRA2C—medulla oblongata—brain cancer	0.000722	0.00147	CbGeAlD
Loxapine—DRD1—brain—brain cancer	0.000722	0.00147	CbGeAlD
Loxapine—HTR7—midbrain—brain cancer	0.000718	0.00146	CbGeAlD
Loxapine—Asthenia—Carmustine—brain cancer	0.000717	0.00267	CcSEcCtD
Loxapine—SLC6A3—cerebellum—brain cancer	0.000714	0.00145	CbGeAlD
Loxapine—HTR1D—central nervous system—brain cancer	0.000713	0.00145	CbGeAlD
Loxapine—Hypersensitivity—Temozolomide—brain cancer	0.000712	0.00265	CcSEcCtD
Loxapine—HTR2C—central nervous system—brain cancer	0.000706	0.00144	CbGeAlD
Loxapine—HTR2A—brainstem—brain cancer	0.000702	0.00143	CbGeAlD
Loxapine—HTR7—spinal cord—brain cancer	0.0007	0.00142	CbGeAlD
Loxapine—HTR3A—brain—brain cancer	0.000697	0.00142	CbGeAlD
Loxapine—Paraesthesia—Etoposide—brain cancer	0.000694	0.00259	CcSEcCtD
Loxapine—Asthenia—Temozolomide—brain cancer	0.000693	0.00258	CcSEcCtD
Loxapine—ADRB1—central nervous system—brain cancer	0.000693	0.00141	CbGeAlD
Loxapine—Dyspnoea—Etoposide—brain cancer	0.000689	0.00257	CcSEcCtD
Loxapine—Somnolence—Etoposide—brain cancer	0.000687	0.00256	CcSEcCtD
Loxapine—Pruritus—Temozolomide—brain cancer	0.000684	0.00255	CcSEcCtD
Loxapine—DRD2—midbrain—brain cancer	0.000679	0.00138	CbGeAlD
Loxapine—SLC6A4—central nervous system—brain cancer	0.000669	0.00136	CbGeAlD
Loxapine—Gastrointestinal disorder—Etoposide—brain cancer	0.000667	0.00249	CcSEcCtD
Loxapine—CHRM1—central nervous system—brain cancer	0.000667	0.00136	CbGeAlD
Loxapine—Fatigue—Etoposide—brain cancer	0.000667	0.00248	CcSEcCtD
Loxapine—CHRM3—endocrine gland—brain cancer	0.000662	0.00135	CbGeAlD
Loxapine—Dizziness—Carmustine—brain cancer	0.000661	0.00246	CcSEcCtD
Loxapine—Constipation—Etoposide—brain cancer	0.000661	0.00246	CcSEcCtD
Loxapine—ADRA2C—midbrain—brain cancer	0.00066	0.00134	CbGeAlD
Loxapine—HTR1A—endocrine gland—brain cancer	0.00066	0.00134	CbGeAlD
Loxapine—SLC6A2—endocrine gland—brain cancer	0.000654	0.00133	CbGeAlD
Loxapine—CHRM3—head—brain cancer	0.000654	0.00133	CbGeAlD
Loxapine—HTR1A—head—brain cancer	0.000651	0.00132	CbGeAlD
Loxapine—SLC6A2—head—brain cancer	0.000646	0.00131	CbGeAlD
Loxapine—ADRA2C—spinal cord—brain cancer	0.000644	0.00131	CbGeAlD
Loxapine—Dizziness—Temozolomide—brain cancer	0.000639	0.00238	CcSEcCtD
Loxapine—Feeling abnormal—Etoposide—brain cancer	0.000637	0.00237	CcSEcCtD
Loxapine—Vomiting—Carmustine—brain cancer	0.000636	0.00237	CcSEcCtD
Loxapine—HTR7—endocrine gland—brain cancer	0.00063	0.00128	CbGeAlD
Loxapine—Rash—Carmustine—brain cancer	0.00063	0.00235	CcSEcCtD
Loxapine—Dermatitis—Carmustine—brain cancer	0.00063	0.00235	CcSEcCtD
Loxapine—Headache—Carmustine—brain cancer	0.000626	0.00233	CcSEcCtD
Loxapine—HTR2A—telencephalon—brain cancer	0.000623	0.00127	CbGeAlD
Loxapine—HTR7—head—brain cancer	0.000622	0.00127	CbGeAlD
Loxapine—Vomiting—Temozolomide—brain cancer	0.000614	0.00229	CcSEcCtD
Loxapine—ADRA2A—gonad—brain cancer	0.000612	0.00124	CbGeAlD
Loxapine—Rash—Temozolomide—brain cancer	0.000609	0.00227	CcSEcCtD
Loxapine—Dermatitis—Temozolomide—brain cancer	0.000609	0.00227	CcSEcCtD
Loxapine—ADRA1A—endocrine gland—brain cancer	0.000608	0.00124	CbGeAlD
Loxapine—Headache—Temozolomide—brain cancer	0.000605	0.00226	CcSEcCtD
Loxapine—ADRA1A—head—brain cancer	0.0006	0.00122	CbGeAlD
Loxapine—ADRA2A—pituitary gland—brain cancer	0.000597	0.00121	CbGeAlD
Loxapine—CHRM3—central nervous system—brain cancer	0.000597	0.00121	CbGeAlD
Loxapine—DRD2—endocrine gland—brain cancer	0.000596	0.00121	CbGeAlD
Loxapine—HTR1A—central nervous system—brain cancer	0.000594	0.00121	CbGeAlD
Loxapine—Nausea—Carmustine—brain cancer	0.000594	0.00221	CcSEcCtD
Loxapine—SLC6A2—central nervous system—brain cancer	0.000589	0.0012	CbGeAlD
Loxapine—DRD2—head—brain cancer	0.000588	0.0012	CbGeAlD
Loxapine—HTR1B—brain—brain cancer	0.000585	0.00119	CbGeAlD
Loxapine—CHRM2—brain—brain cancer	0.000582	0.00118	CbGeAlD
Loxapine—HTR1A—cerebellum—brain cancer	0.000581	0.00118	CbGeAlD
Loxapine—SLC6A3—brain—brain cancer	0.00058	0.00118	CbGeAlD
Loxapine—ADRA2A—medulla oblongata—brain cancer	0.000576	0.00117	CbGeAlD
Loxapine—Nausea—Temozolomide—brain cancer	0.000574	0.00214	CcSEcCtD
Loxapine—ADRA2C—head—brain cancer	0.000572	0.00116	CbGeAlD
Loxapine—Hypersensitivity—Etoposide—brain cancer	0.00057	0.00212	CcSEcCtD
Loxapine—HTR7—central nervous system—brain cancer	0.000568	0.00116	CbGeAlD
Loxapine—HTR1D—brain—brain cancer	0.000566	0.00115	CbGeAlD
Loxapine—HTR2C—brain—brain cancer	0.000561	0.00114	CbGeAlD
Loxapine—HTR7—cerebellum—brain cancer	0.000555	0.00113	CbGeAlD
Loxapine—Asthenia—Etoposide—brain cancer	0.000555	0.00207	CcSEcCtD
Loxapine—ADRB1—brain—brain cancer	0.00055	0.00112	CbGeAlD
Loxapine—ADRA1A—central nervous system—brain cancer	0.000548	0.00111	CbGeAlD
Loxapine—Pruritus—Etoposide—brain cancer	0.000547	0.00204	CcSEcCtD
Loxapine—DRD2—central nervous system—brain cancer	0.000537	0.00109	CbGeAlD
Loxapine—ADRA1A—cerebellum—brain cancer	0.000536	0.00109	CbGeAlD
Loxapine—SLC6A4—brain—brain cancer	0.000532	0.00108	CbGeAlD
Loxapine—CHRM1—brain—brain cancer	0.000529	0.00108	CbGeAlD
Loxapine—ADRA2A—midbrain—brain cancer	0.000526	0.00107	CbGeAlD
Loxapine—DRD2—cerebellum—brain cancer	0.000525	0.00107	CbGeAlD
Loxapine—ADRA2C—central nervous system—brain cancer	0.000522	0.00106	CbGeAlD
Loxapine—HTR2A—gonad—brain cancer	0.00052	0.00106	CbGeAlD
Loxapine—ADRA2A—spinal cord—brain cancer	0.000514	0.00104	CbGeAlD
Loxapine—Dizziness—Etoposide—brain cancer	0.000511	0.00191	CcSEcCtD
Loxapine—ADRA2C—cerebellum—brain cancer	0.00051	0.00104	CbGeAlD
Loxapine—HTR2A—pituitary gland—brain cancer	0.000507	0.00103	CbGeAlD
Loxapine—Vomiting—Etoposide—brain cancer	0.000492	0.00183	CcSEcCtD
Loxapine—HTR2A—medulla oblongata—brain cancer	0.00049	0.000996	CbGeAlD
Loxapine—Rash—Etoposide—brain cancer	0.000487	0.00182	CcSEcCtD
Loxapine—Dermatitis—Etoposide—brain cancer	0.000487	0.00181	CcSEcCtD
Loxapine—Headache—Etoposide—brain cancer	0.000484	0.0018	CcSEcCtD
Loxapine—CHRM3—brain—brain cancer	0.000474	0.000964	CbGeAlD
Loxapine—HTR1A—brain—brain cancer	0.000472	0.00096	CbGeAlD
Loxapine—HRH1—endocrine gland—brain cancer	0.000471	0.000958	CbGeAlD
Loxapine—SLC6A2—brain—brain cancer	0.000468	0.000952	CbGeAlD
Loxapine—HRH1—head—brain cancer	0.000465	0.000945	CbGeAlD
Loxapine—ADRA2A—endocrine gland—brain cancer	0.000462	0.000941	CbGeAlD
Loxapine—Nausea—Etoposide—brain cancer	0.000459	0.00171	CcSEcCtD
Loxapine—ADRA2A—head—brain cancer	0.000456	0.000929	CbGeAlD
Loxapine—HTR7—brain—brain cancer	0.000451	0.000918	CbGeAlD
Loxapine—HTR2A—midbrain—brain cancer	0.000448	0.000911	CbGeAlD
Loxapine—HTR2A—spinal cord—brain cancer	0.000437	0.000888	CbGeAlD
Loxapine—ADRA1A—brain—brain cancer	0.000435	0.000885	CbGeAlD
Loxapine—DRD2—brain—brain cancer	0.000426	0.000868	CbGeAlD
Loxapine—HRH1—central nervous system—brain cancer	0.000424	0.000863	CbGeAlD
Loxapine—ADRA2A—central nervous system—brain cancer	0.000417	0.000848	CbGeAlD
Loxapine—ADRA2C—brain—brain cancer	0.000415	0.000843	CbGeAlD
Loxapine—ADRA2A—cerebellum—brain cancer	0.000407	0.000828	CbGeAlD
Loxapine—HTR2A—endocrine gland—brain cancer	0.000393	0.0008	CbGeAlD
Loxapine—HTR2A—head—brain cancer	0.000388	0.00079	CbGeAlD
Loxapine—HTR2A—central nervous system—brain cancer	0.000354	0.000721	CbGeAlD
Loxapine—HTR2A—cerebellum—brain cancer	0.000346	0.000704	CbGeAlD
Loxapine—HRH1—brain—brain cancer	0.000337	0.000685	CbGeAlD
Loxapine—ADRA2A—brain—brain cancer	0.000331	0.000673	CbGeAlD
Loxapine—HTR2A—brain—brain cancer	0.000281	0.000572	CbGeAlD
Loxapine—ADRA2B—Signaling by GPCR—EGFR—brain cancer	1.95e-05	8.68e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—IL2—brain cancer	1.95e-05	8.67e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—EGFR—brain cancer	1.95e-05	8.66e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CG—brain cancer	1.95e-05	8.64e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—IL2—brain cancer	1.94e-05	8.61e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—CCND1—brain cancer	1.92e-05	8.52e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—CCND1—brain cancer	1.92e-05	8.51e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—IL2—brain cancer	1.91e-05	8.49e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—CCND1—brain cancer	1.9e-05	8.46e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—CTNNB1—brain cancer	1.9e-05	8.44e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—CTNNB1—brain cancer	1.9e-05	8.43e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—EGFR—brain cancer	1.89e-05	8.38e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—CTNNB1—brain cancer	1.89e-05	8.37e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—IL2—brain cancer	1.88e-05	8.36e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—RELA—brain cancer	1.88e-05	8.35e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—EGFR—brain cancer	1.88e-05	8.33e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—ERBB2—brain cancer	1.87e-05	8.3e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—CCND1—brain cancer	1.86e-05	8.28e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—IL2—brain cancer	1.86e-05	8.25e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—RELA—brain cancer	1.86e-05	8.24e-05	CbGpPWpGaD
Loxapine—HTR1E—Signaling Pathways—TP53—brain cancer	1.85e-05	8.22e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—CTNNB1—brain cancer	1.85e-05	8.2e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—ERBB2—brain cancer	1.84e-05	8.19e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IRS2—brain cancer	1.84e-05	8.18e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—CCND1—brain cancer	1.83e-05	8.15e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—EGFR—brain cancer	1.82e-05	8.11e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—APC—brain cancer	1.82e-05	8.07e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CG—brain cancer	1.82e-05	8.07e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—CTNNB1—brain cancer	1.82e-05	8.07e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—CCND1—brain cancer	1.81e-05	8.04e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—EGFR—brain cancer	1.8e-05	7.98e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—CTNNB1—brain cancer	1.79e-05	7.96e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CG—brain cancer	1.79e-05	7.94e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—APC—brain cancer	1.79e-05	7.94e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—APC—brain cancer	1.78e-05	7.93e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CG—brain cancer	1.78e-05	7.93e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—APC—brain cancer	1.78e-05	7.9e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CG—brain cancer	1.78e-05	7.9e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—IL2—brain cancer	1.78e-05	7.9e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—APC—brain cancer	1.77e-05	7.88e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CG—brain cancer	1.77e-05	7.88e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CG—brain cancer	1.76e-05	7.8e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—APC—brain cancer	1.76e-05	7.8e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—APC—brain cancer	1.75e-05	7.78e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CG—brain cancer	1.75e-05	7.78e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—CCND1—brain cancer	1.73e-05	7.7e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—CTNNB1—brain cancer	1.72e-05	7.62e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—IL2—brain cancer	1.69e-05	7.52e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—RELA—brain cancer	1.69e-05	7.51e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—ERBB2—brain cancer	1.68e-05	7.46e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—RELA—brain cancer	1.68e-05	7.44e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—VEGFA—brain cancer	1.67e-05	7.43e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—IL2—brain cancer	1.67e-05	7.42e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—VEGFA—brain cancer	1.67e-05	7.42e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—ERBB2—brain cancer	1.67e-05	7.4e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—VEGFA—brain cancer	1.66e-05	7.37e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—STAT3—brain cancer	1.66e-05	7.36e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—EGFR—brain cancer	1.66e-05	7.36e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—STAT3—brain cancer	1.65e-05	7.35e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—CCND1—brain cancer	1.65e-05	7.34e-05	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—TP53—brain cancer	1.65e-05	7.32e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—STAT3—brain cancer	1.64e-05	7.3e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—TP53—brain cancer	1.64e-05	7.27e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—CTNNB1—brain cancer	1.64e-05	7.26e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—CCND1—brain cancer	1.63e-05	7.24e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—EGFR—brain cancer	1.63e-05	7.24e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—APC—brain cancer	1.63e-05	7.23e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CG—brain cancer	1.63e-05	7.23e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—EGFR—brain cancer	1.63e-05	7.22e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—VEGFA—brain cancer	1.63e-05	7.22e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—EGFR—brain cancer	1.62e-05	7.2e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—RELA—brain cancer	1.62e-05	7.18e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—EGFR—brain cancer	1.62e-05	7.18e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—CTNNB1—brain cancer	1.61e-05	7.17e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—STAT3—brain cancer	1.61e-05	7.15e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—RELA—brain cancer	1.61e-05	7.15e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—ERBB2—brain cancer	1.61e-05	7.14e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—EGFR—brain cancer	1.6e-05	7.11e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—VEGFA—brain cancer	1.6e-05	7.1e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—ERBB2—brain cancer	1.6e-05	7.1e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—EGFR—brain cancer	1.6e-05	7.09e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—STAT3—brain cancer	1.58e-05	7.03e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—VEGFA—brain cancer	1.58e-05	7.01e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—RELA—brain cancer	1.57e-05	6.95e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—STAT3—brain cancer	1.56e-05	6.94e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—ERBB2—brain cancer	1.56e-05	6.91e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—RELA—brain cancer	1.54e-05	6.84e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—MYC—brain cancer	1.54e-05	6.83e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—MYC—brain cancer	1.54e-05	6.83e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—ERBB2—brain cancer	1.53e-05	6.8e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—MYC—brain cancer	1.53e-05	6.78e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—IL2—brain cancer	1.52e-05	6.76e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—VEGFA—brain cancer	1.51e-05	6.71e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—IL2—brain cancer	1.51e-05	6.7e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—EGFR—brain cancer	1.51e-05	6.69e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—EGFR—brain cancer	1.5e-05	6.68e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—STAT3—brain cancer	1.5e-05	6.64e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—MYC—brain cancer	1.5e-05	6.64e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—EGFR—brain cancer	1.49e-05	6.63e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CCND1—brain cancer	1.48e-05	6.59e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—EGFR—brain cancer	1.48e-05	6.58e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—MYC—brain cancer	1.47e-05	6.54e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CCND1—brain cancer	1.47e-05	6.53e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—CTNNB1—brain cancer	1.47e-05	6.53e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—EGFR—brain cancer	1.46e-05	6.5e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—CTNNB1—brain cancer	1.46e-05	6.47e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—IL2—brain cancer	1.46e-05	6.47e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—MYC—brain cancer	1.45e-05	6.45e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—IL2—brain cancer	1.45e-05	6.44e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—VEGFA—brain cancer	1.44e-05	6.39e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—EGFR—brain cancer	1.44e-05	6.39e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—STAT3—brain cancer	1.43e-05	6.33e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—VEGFA—brain cancer	1.42e-05	6.31e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—RELA—brain cancer	1.42e-05	6.31e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CCND1—brain cancer	1.42e-05	6.31e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—EGFR—brain cancer	1.42e-05	6.31e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CCND1—brain cancer	1.41e-05	6.28e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—ERBB2—brain cancer	1.41e-05	6.27e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL2—brain cancer	1.41e-05	6.26e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—STAT3—brain cancer	1.41e-05	6.25e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—CTNNB1—brain cancer	1.41e-05	6.25e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—CTNNB1—brain cancer	1.4e-05	6.21e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—RELA—brain cancer	1.4e-05	6.21e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—RELA—brain cancer	1.39e-05	6.19e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MYC—brain cancer	1.39e-05	6.17e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—RELA—brain cancer	1.39e-05	6.17e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—ERBB2—brain cancer	1.39e-05	6.17e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL2—brain cancer	1.39e-05	6.16e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—ERBB2—brain cancer	1.39e-05	6.15e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—RELA—brain cancer	1.39e-05	6.15e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—ERBB2—brain cancer	1.38e-05	6.13e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—ERBB2—brain cancer	1.38e-05	6.12e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCND1—brain cancer	1.37e-05	6.1e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—RELA—brain cancer	1.37e-05	6.09e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—RELA—brain cancer	1.37e-05	6.08e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—ERBB2—brain cancer	1.36e-05	6.06e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CTNNB1—brain cancer	1.36e-05	6.04e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—EGFR—brain cancer	1.36e-05	6.04e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—ERBB2—brain cancer	1.36e-05	6.04e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCND1—brain cancer	1.35e-05	6.01e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CTNNB1—brain cancer	1.34e-05	5.95e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MYC—brain cancer	1.32e-05	5.88e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MYC—brain cancer	1.31e-05	5.81e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—EGFR—brain cancer	1.3e-05	5.75e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—VEGFA—brain cancer	1.29e-05	5.75e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—VEGFA—brain cancer	1.28e-05	5.7e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—STAT3—brain cancer	1.28e-05	5.69e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL2—brain cancer	1.28e-05	5.68e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—EGFR—brain cancer	1.28e-05	5.68e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—RELA—brain cancer	1.27e-05	5.65e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—STAT3—brain cancer	1.27e-05	5.64e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TP53—brain cancer	1.26e-05	5.61e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—ERBB2—brain cancer	1.26e-05	5.61e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TP53—brain cancer	1.26e-05	5.61e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL2—brain cancer	1.26e-05	5.59e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL2—brain cancer	1.26e-05	5.58e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TP53—brain cancer	1.25e-05	5.57e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL2—brain cancer	1.25e-05	5.56e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL2—brain cancer	1.25e-05	5.54e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCND1—brain cancer	1.25e-05	5.54e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—brain cancer	1.24e-05	5.5e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL2—brain cancer	1.24e-05	5.49e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CTNNB1—brain cancer	1.23e-05	5.48e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL2—brain cancer	1.23e-05	5.47e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—brain cancer	1.23e-05	5.47e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—brain cancer	1.23e-05	5.45e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCND1—brain cancer	1.23e-05	5.45e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—STAT3—brain cancer	1.23e-05	5.44e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCND1—brain cancer	1.22e-05	5.44e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCND1—brain cancer	1.22e-05	5.42e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—STAT3—brain cancer	1.22e-05	5.42e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCND1—brain cancer	1.22e-05	5.4e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CTNNB1—brain cancer	1.21e-05	5.4e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CTNNB1—brain cancer	1.21e-05	5.38e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CTNNB1—brain cancer	1.21e-05	5.37e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—brain cancer	1.21e-05	5.37e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCND1—brain cancer	1.2e-05	5.35e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CTNNB1—brain cancer	1.2e-05	5.35e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCND1—brain cancer	1.2e-05	5.34e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—brain cancer	1.2e-05	5.32e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CTNNB1—brain cancer	1.19e-05	5.3e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—brain cancer	1.19e-05	5.29e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—brain cancer	1.19e-05	5.29e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CTNNB1—brain cancer	1.19e-05	5.28e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—brain cancer	1.19e-05	5.27e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—brain cancer	1.18e-05	5.24e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—brain cancer	1.18e-05	5.24e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—brain cancer	1.17e-05	5.19e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—brain cancer	1.16e-05	5.17e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—brain cancer	1.15e-05	5.13e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—brain cancer	1.14e-05	5.09e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—brain cancer	1.14e-05	5.07e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—brain cancer	1.14e-05	5.06e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—brain cancer	1.13e-05	5.03e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—brain cancer	1.12e-05	4.96e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—brain cancer	1.11e-05	4.95e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—brain cancer	1.11e-05	4.92e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CTNNB1—brain cancer	1.11e-05	4.91e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—brain cancer	1.1e-05	4.9e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—brain cancer	1.09e-05	4.83e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—brain cancer	1.09e-05	4.83e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—brain cancer	1.08e-05	4.82e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—brain cancer	1.08e-05	4.79e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—brain cancer	1.08e-05	4.78e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—brain cancer	1.07e-05	4.77e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—brain cancer	1.07e-05	4.75e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—brain cancer	1.07e-05	4.74e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—brain cancer	1.06e-05	4.73e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—brain cancer	1.06e-05	4.71e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—brain cancer	1.06e-05	4.71e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—brain cancer	1.06e-05	4.7e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—brain cancer	1.06e-05	4.69e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—brain cancer	1.05e-05	4.68e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—brain cancer	1.05e-05	4.66e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—brain cancer	1.05e-05	4.66e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—brain cancer	1.05e-05	4.65e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—brain cancer	1.04e-05	4.62e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—brain cancer	1.04e-05	4.61e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—brain cancer	1e-05	4.44e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—brain cancer	9.84e-06	4.37e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—brain cancer	9.82e-06	4.36e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—brain cancer	9.79e-06	4.35e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—brain cancer	9.78e-06	4.34e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—brain cancer	9.78e-06	4.34e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—brain cancer	9.76e-06	4.33e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—brain cancer	9.73e-06	4.32e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—brain cancer	9.69e-06	4.3e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—brain cancer	9.66e-06	4.29e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—brain cancer	9.64e-06	4.28e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—brain cancer	9.63e-06	4.28e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—brain cancer	9.63e-06	4.28e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—brain cancer	9.6e-06	4.27e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—brain cancer	9.57e-06	4.25e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—brain cancer	9.54e-06	4.24e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—brain cancer	9.45e-06	4.2e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—brain cancer	9.42e-06	4.19e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—brain cancer	9.35e-06	4.15e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—brain cancer	9.31e-06	4.13e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—brain cancer	9.05e-06	4.02e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—brain cancer	8.95e-06	3.98e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—brain cancer	8.91e-06	3.96e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—brain cancer	8.76e-06	3.89e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—brain cancer	8.21e-06	3.65e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—brain cancer	8.08e-06	3.59e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—brain cancer	8.06e-06	3.58e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—brain cancer	8.04e-06	3.57e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—brain cancer	8.01e-06	3.56e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—brain cancer	7.93e-06	3.52e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—brain cancer	7.91e-06	3.51e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—brain cancer	7.35e-06	3.27e-05	CbGpPWpGaD
